Synlogic Has Initiated Its Synpheny-3 Phase 3 Study Evaluating The Efficacy And Safety Of SYNB1934 As A Potential Treatment For Phenylketonuria, the Study Will Enroll Approximately 150 Patients
Portfolio Pulse from Benzinga Newsdesk
Synlogic has initiated its Synpheny-3 Phase 3 study to evaluate the efficacy and safety of SYNB1934 as a potential treatment for Phenylketonuria. The study will enroll approximately 150 patients.
June 05, 2023 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Synlogic's initiation of the Synpheny-3 Phase 3 study for SYNB1934 may positively impact its stock price as it progresses in the development of a potential treatment for Phenylketonuria.
The initiation of the Synpheny-3 Phase 3 study for SYNB1934 is a significant milestone for Synlogic, as it indicates progress in the development of a potential treatment for Phenylketonuria. This news may be seen as positive by investors, leading to a potential increase in the stock price of Synlogic (SYBX) in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100